ROBERT C. KOSKI - 08 Aug 2023 Form 4 Insider Report for ORAGENICS INC (OGEN)

Role
Director
Signature
/s/ Mark A. Catchur, as Attorney-in-Fact for Robert C. Koski
Issuer symbol
OGEN
Transactions as of
08 Aug 2023
Net transactions value
$0
Form type
4
Filing time
10 Aug 2023, 16:30:35 UTC
Previous filing
03 Jan 2023
Next filing
22 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGEN Common Stock Award $0 +25,000 +3628% $0.000000 25,689 08 Aug 2023 Direct F1, F2
holding OGEN Common Stock 18,367 08 Aug 2023 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock pursuant to the Company's non-employee director compensation program under the Company's 2021 Equity Incentive Plan with 20,000 shares vesting immediately and 5,000 shares vesting in six (6) months.
F2 Reflects adjustments made in connection with the 1-for-60 reverse stock split of the Issuer's common stock which became effective on January 23, 2023.
F3 Represents shares owned by the Koski Family Limited Partnership ("KFLP"). The reporting person serves as one of the general partners of the KFLP and disclaims beneficial ownership of the securities reflected as held by the KFLP except to the extent of the reporting person's pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.